Expression of the COVID-19 receptor ACE2 in the human conjunctiva.
J Med Virol
; 92(10): 2081-2086, 2020 10.
Article
en En
| MEDLINE
| ID: mdl-32374427
ABSTRACT
SARS-CoV-2 is assumed to use angiotensin-converting enzyme 2 (ACE2) and other auxiliary proteins for cell entry. Recent studies have described conjunctival congestion in 0.8% of patients with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and there has been speculation that SARS-CoV-2 can be transmitted through the conjunctiva. However, it is currently unclear whether conjunctival epithelial cells express ACE2 and its cofactors. In this study, a total of 38 conjunctival samples from 38 patients, including 12 healthy conjunctivas, 12 melanomas, seven squamous cell carcinomas, and seven papilloma samples, were analyzed using high-throughput RNA sequencing to assess messenger RNA (mRNA) expression of the SARS-CoV-2 receptor ACE2 and its cofactors including TMPRSS2, ANPEP, DPP4, and ENPEP. ACE2 protein expression was assessed in eight healthy conjunctival samples using immunohistochemistry. Our results show that the SARS-CoV-2 receptor ACE2 is not substantially expressed in conjunctival samples on the mRNA (median 0.0 transcripts per million [TPM], min 0.0 TPM, max 1.7 TPM) and protein levels. Similar results were obtained for the transcription of other auxiliary molecules. In conclusion, this study finds no evidence for a significant expression of ACE2 and its auxiliary mediators for cell entry in conjunctival samples, making conjunctival infection with SARS-CoV-2 via these mediators unlikely.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Papiloma
/
Receptores Virales
/
Carcinoma de Células Escamosas
/
Neoplasias del Ojo
/
COVID-19
/
Melanoma
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Aged80
Idioma:
En
Revista:
J Med Virol
Año:
2020
Tipo del documento:
Article
País de afiliación:
Alemania